Advanced in Essential Thrombocythemia

Dr. Shobha R. Chitneni

State University Of Iowa
Bettendorf, IA
Advanced
in Essential Thrombocythemia
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
OverviewInsuranceLocationsClinical Research

Overview

Shobha Chitneni is a Hematologist Oncology specialist and a Hematologist in Bettendorf, Iowa. Mrs. Chitneni and is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Intraductal Papilloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Paget Disease of the Breast, Osteosarcoma, and Bone Marrow Aspiration. Mrs. Chitneni is currently accepting new patients.

Her clinical research consists of participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Specialist in IA
Hospital Affiliations
University Of Iowa Hospital & Clinics
Genesis Medical Center-Davenport
Genesis Medical Center-Dewitt
Trinity Rock Island
Languages Spoken
English
Hindi
Telugu
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Sanford Health
  •  Wellmark
  •  Medica
  •  Blue Cross Blue Shield
  •  Humana

Locations

STATE UNIVERSITY OF IOWA
1351 Kimberly Rd, Suite 100, Bettendorf, IA 52722
563-355-7733

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2024
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials
Similar Doctors
Expertise in
57
conditions
Dr. Anoop Aggarwal
Hematology Oncology | Hematology | Oncology
Expertise in
57
conditions
Dr. Anoop Aggarwal
Hematology Oncology | Hematology | Oncology

Genesis Health System

1351 W Central Park Ave, Mercyone Genesis, 
Davenport, IA 
 (3.8 mi)
563-421-1900
Languages Spoken:
English, Shona, Sign Language
See accepted insurances
Accepting New Patients

Anoop Aggarwal is a Hematologist Oncology specialist and a Hematologist in Davenport, Iowa. Dr. Aggarwal and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Paget Disease of the Breast, Colorectal Cancer, Familial Colorectal Cancer, and Anemia. Dr. Aggarwal is currently accepting new patients.

Expertise in
82
conditions
Dr. Mir A. Alikhan
Hematology Oncology | Hematology | Oncology
Expertise in
82
conditions
Dr. Mir A. Alikhan
Hematology Oncology | Hematology | Oncology

Cgh Medical Center

101 E Miller Rd, 
Sterling, IL 
 (46.4 mi)
815-625-4790
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mir Alikhan is a Hematologist Oncology specialist and a Hematologist in Sterling, Illinois. Dr. Alikhan and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, and Iron Deficiency Anemia.

Expertise in
75
conditions
Dr. Michael G. Porubcin
Hematology Oncology | Oncology | Hematology
Expertise in
75
conditions
Dr. Michael G. Porubcin
Hematology Oncology | Oncology | Hematology

Genesis Health System

801 Illini Dr, 
Silvis, IL 
 (5.9 mi)
309-281-4000
Languages Spoken:
English, Czech
See accepted insurances
Accepting New Patients

Michael Porubcin is a Hematologist Oncology specialist and an Oncologist in Silvis, Illinois. Dr. Porubcin and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Porubcin is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile